Audit: QRS - Ashwagandha for Health & Longevity

Audit conducted on 02/09/2026 03:40 using AI4L / Opus 5

Iterations

Summary

Items	Count
Total	93
Passed	85
Failed	0
N/A	8
Pass Rate	100.00%

• Total = Passed + Failed + N/A
• Pass Rate = Passed / (Passed + Failed) × 100
• N/A items are excluded from the pass rate calculation

---

1. General Rules

#	Description	Result	Comments
1.1	Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER.	🟢	Spot-checked all variable regions against the ER: protocol cells vs. ER Therapeutic Protocol, time cells vs. ER Practical Considerations time-to-effect bullet, benefit/risk tiers vs. ER H4 headings, gates vs. ER Key Interactions & Contraindications, all 10 marker rows and cadence vs. the ER monitoring table and its two lead paragraphs.
1.2	Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing.	🟢	“Memory gains are less certain” mirrors ER “consistent though less certain”; “no human lifespan data” mirrors ER “No human longevity data exist”.
1.3	The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”).	🟢	Pregnancy, transplant and chronic-liver-disease entries remain in the Contraindications gate at ER strength; nothing demoted to caution.
1.4	The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc.	🟢	Contraindications come only from the ER “Populations who should avoid Ashwagandha” list; interactions only from the ER interaction bullets; risk tiers only from ER Potential Risks & Side Effects H4 headings. No modifying-factor content migrated.
1.5	PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact.	🟢	No PMIDs, citations, author names or NCT IDs present. KSM-66 and Sensoril appear only in [action_2_sub], matching the ER Therapeutic Protocol “Extract selection” bullet.
1.6	The QRS does not introduce new attributions.	🟢	No attributions of any kind added.

2. Focus, Tone & Audience

#	Description	Result	Comments
2.1	The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing.	🟢	Terse declarative register matching the ER’s; the ER’s evenhanded benefit/harm framing is carried through in [at_a_glance].
2.2	The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging	🟢
2.3	The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor	🟢	Gates and cadence are stated as noun phrases, not instructions to a patient.
2.4	The QRS avoids language that implies medical or clinical advice	🟢	No imperatives; “is preferred”, “is the common lower-tier protocol” describe practice rather than direct the reader.
2.5	The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising”	🟢	[monitoring_cadence] is phrased as a schedule (“Liver panel before starting; liver enzymes at 8–12 weeks, then annually”), not as a recommendation.
2.6	The QRS never addresses “the reader” directly — it presents evidence, not guidance	🟢	No second-person pronouns anywhere in the body.
2.7	The QRS is written in plain language, avoiding unnecessary medical jargon	🟢	Retained technical terms (alanine aminotransferase, Child-Pugh A–C, thyrotoxicosis) are marker names and staging classes that items 8.5 and 14.2 require to be preserved.
2.8	Information is presented in a concise and very compact manner	🟢	ER Conclusion (3 paragraphs) → 59 words; 12 ER protocol bullets → 3 cells; interaction bullets stripped to drug class plus examples.
2.9	It DOES NOT address the reader directly	🟢	Verified: no “you”/”your” tokens in the rendered content.
2.10	The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review.	🟢
2.11	The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort.	🟢	Baseline and 8–12 week liver panels, third-party-tested named extracts and repeated questionnaires assume this willingness.
2.12	The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort.	🟢
2.13	Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience.	🟢	[at_a_glance] foregrounds the liver-injury signal and sponsor funding alongside the benefits, matching the ER’s weighting for a risk-aware reader.
2.14	The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim.	🟢	No occurrence of “anti-aging”; the title carries “Longevity”.
2.15	The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt.	🟢	“Gastrointestinal upset”, “daytime drowsiness and sedation”, “herb-induced liver injury” — all formal register, all ER wording.

3. Template Integrity

#	Description	Result	Comments
3.1	The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why”	🟢	All fifteen fixed strings present verbatim (lines 446, 492, 542, 576, 601, 623, 651, 656–658, 785 and the four tier labels in each of the Benefits and Risks cards).
3.2	All “…” from the [qrs_template] are present in the the QRS.	🟢	All 38 template variable names present; marker_#_* expanded to markers 1–10 and qualitative_item_# to items 1–8, giving 72 variable spans plus the 3 untouched website= spans, with balanced open/close tags.
3.3	Spans that are not addressed in a checklist item are left unchanged	🟢	<span website="evidence_review">, <span website="audit"> and <span website="full_review"> are byte-identical to the template.

4. Formatting

#	Description	Result	Comments
4.1	When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied”	N/A	No source ER section that feeds the QRS is empty.
4.2	Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label.	🟢	“Standard dose”, “Extract selection” and “Best time of day” match the ER Therapeutic Protocol bold labels verbatim.
4.3	Labels are not paraphrased, abbreviated, or invented.	🟢	Benefit and risk items reuse ER H4 headings verbatim; marker names match the ER monitoring table’s Biomarker column.
4.4	The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels.	🟢	No emoji present; the ER’s “⚠️ Conflicted” markers were correctly stripped from the transferred benefit and risk headings.
4.5	The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page.	🟢	Every section was condensed rather than transcribed: ER mitigation sentences, magnitudes and citations dropped from the gates; marker rationales cut to a single clause; qualitative markers trimmed of their trailing explanations.

---

5. Metadata

#	Description	Result	Comments
5.1	The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content.	🟢	Lines 2–14, immediately after <!doctype html> on line 1.
5.2	Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML.	🟢	Opening --- on line 3, closing --- on line 13.
5.3	The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet.	🟢	Enclosed in an HTML comment; no metadata value is repeated in the header or footer.
5.4	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Only duration: "00:03" is quoted, and it contains a colon.
5.5	The filename of the source ER is stated as “er_filename: [er_filename]”	🟢	Line 4: er_filename: ashwagandha_2026-0902-0007_Opus_ER.md.
5.6	Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”	🟢	Line 5: qrs_prompt_version: 26.7.02, matching the QRS.md version badge.
5.7	Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430)	🟢	Line 6: qrs_creation_date: 2026-0902-0317.
5.8	The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]”	🟢	Line 7: qrs_creator_ai_nickname: Opus.
5.9	The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT)	🟢	“Opus” — single word, no version.
5.10	The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]”	🟢	Line 8: qrs_creator_ai_fullname: Opus 5.
5.11	The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4)	🟢	“Opus 5” — nickname plus version, no qualifier.
5.12	The filename of the document is stated as “qrs_filename: [filename of this document]”	🟢	Line 9 matches the file’s actual name, ashwagandha_2026-0902-0007_Opus_QRS.html.
5.13	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Re-verified across all ten keys, including git_user and git_issue.

6. Page Title & Header

#	Description	Result	Comments
6.1	[page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &)	🟢	Line 22: Ashwagandha for Health & Longevity - Quick Reference Sheet, matching ER canonical_topic with the ampersand encoded.
6.2	[header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &)	🟢	Line 417: Ashwagandha for Health & Longevity.
6.3	[header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]	🟢	Line 421: 09/02/2026, correct for creation date 2026-0902-0317.
6.4	[header_subline_model] is set to [qrs_creator_ai_fullname]	🟢	Line 425: Opus 5.
6.5	No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker.	🟢	The ER’s “Also known as” line (Withania somnifera, Indian Ginseng, …) was correctly not carried over.

7. At-A-Glance Section

#	Description	Result	Comments
7.1	[at_a_glance] is dense, execution-oriented summary of the ER Conclusion section	🟢	Compresses all three Conclusion paragraphs: the three clearest benefit domains, the memory caveat, the absent longevity data, the liver and thyroid signals, and the sponsor-funding problem.
7.2	[at_a_glance] is no longer than 60 words	🟢	59 words.
7.3	Every fact in [at_a_glance] is supported by a distinct passage in the ER.	🟢	Each clause traces to a distinct Conclusion sentence; “no human lifespan data” additionally to the ER Speculative benefit “No human longevity data exist”.
7.4	It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead	🟢	No acronyms; “softens the body’s stress response”, “faster sleep onset”, “aerobic capacity”, “liver-injury signal” are all lay-legible.
7.5	It DOES NOT cite specific trials (names, years, sample sizes, p-values)	🟢
7.6	It DOES NOT cite effect sizes, relative risks, or statistical results	🟢	No SMDs, mean differences or confidence intervals carried over from the ER magnitudes.

8. Contraindications

#	Description	Result	Comments
8.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All nine items map one-to-one onto the ER “Populations who should avoid Ashwagandha” list.
8.2	[stop_items] represent the Contraindications from the ER	🟢	All nine ER avoid-list populations are represented; none invented.
8.3	Individual [stop_items] are formatted as <li></li>	🟢	Nine <li> elements inside the span, lines 579–596.
8.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	The ER’s trailing rationale “given the documented testosterone rise in men” was stripped from the prostate-cancer item; no dash-trailing clause survives anywhere in the gate.
8.5	Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	“at any time post-transplant”, “Child-Pugh A–C”, “above 2× upper limit of normal”, “Within two weeks of elective surgery” all preserved.
8.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER uses no ranking notation inside parentheses in this section.
8.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision.	🟢	The ER names nine such populations, and the section is correctly populated rather than empty.
8.8	If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

9. Key Interactions

#	Description	Result	Comments
9.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All ten items map onto ER interaction bullets.
9.2	[caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications	🟢	Immunosuppressants (ER absolute contraindication) and surgery/general anaesthesia are correctly omitted here — both already appear in the Contraindications gate.
9.3	Individual [caution_items] are formatted as <li></li>	🟢	Ten <li> elements inside the span, lines 604–613.
9.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	Every ER “Caution/Monitor” tag, mechanism sentence and “Mitigation:” clause was stripped; the Pattojoshi citation on the antihypertensives bullet was dropped.
9.5	Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Every bullet retains a named example-drug list; longer ER lists were shortened (barbiturates, amiodarone, ciclosporin, efavirenz, magnesium glycinate, turmeric) but never dropped entirely.
9.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER uses no ranking notation inside parentheses in this section.
9.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used.	🟢	The ER names twelve interaction bullets, and the section is correctly populated.
9.8	If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

10. Protocol

#	Description	Result	Comments
10.1	The section is derived from the ER Protocol section	🟢	All three cells trace to the ER Therapeutic Protocol bullets.
10.2	The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section	🟢	Standard dose, extract selection and timing are the three executable levers among the twelve ER bullets; the remainder (framing, attribution, half-life, sex, age, genetics) are contextual rather than actionable.
10.3	If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER supplies well over three actionable aspects; all three sets are used.
10.4	All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section.	🟢	All nine variables populated; e.g. [action_1_value] “600 mg daily” and [action_1_sub] “Root extract standardized to at least 5% withanolides. 300 mg daily is the common lower-tier protocol.” match the ER “Standard dose” bullet.

11. Time to Effect

#	Description	Result	Comments
11.1	The three sets of [time] items cover the three most important time-to-effect aspects from the ER	🟢	Stress/anxiety, sleep and strength/cognition are exactly the domains named in the ER Practical Considerations “Time to effect” bullet.
11.2	The sets are picked and ordered by the magnitude of the related benefit	🟢	Order follows the ER magnitudes: stress/anxiety (SMD −1.55/−1.75) > sleep (−0.59) > strength and memory (0.58 / 0.52).
11.3	If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	Three distinct aspects exist; all three sets are used.
11.4	All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER.	🟢	All nine variables populated; “2–4 weeks”, “2–4 weeks” and “8 weeks” match the ER “emerge at two to four weeks … measured at eight weeks”.
11.5	If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel	N/A	The ER does provide time-to-effect information, so the section is correctly retained.

12. Benefits

#	Description	Result	Comments
12.1	The section is derived from the ER Expected Benefits section	🟢	All fifteen items correspond to the fifteen H4 headings in the ER Expected Benefits section.
12.2	Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]	🟢	All four present and populated, lines 544–569.
12.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Each item is the bare ER heading; every ER “Magnitude:” line, SMD, confidence interval and citation was dropped.
12.4	Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses appear in any of the four benefit spans.
12.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	🟢	All four ER tiers contain items (5 / 3 / 4 / 3), so no span needed hiding and none carries empty-state text.

13. Risks

#	Description	Result	Comments
13.1	The section is derived from the ER Potential Risks & Side Effects section	🟢	All nine items correspond to the nine H4 headings in that ER section.
13.2	Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]	🟢	All four present and populated, lines 625–645.
13.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Latency windows, case counts, the 44%/60% pharmacopoeial figures and all citations were dropped.
13.4	Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	The ER’s parenthetical gloss on thyrotoxicosis was stripped; no parentheses remain in any risk span.
13.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	🟢	All four ER tiers contain items (2 / 2 / 3 / 2); no empty-state phrasing used.

14. Monitoring

#	Description	Result	Comments
14.1	The section is derived from the ER Monitoring section	🟢	Table rows and cadence both trace to the ER Monitoring Protocol & Defining Success section.
14.2	All measurable/quantifiable biomarkers from the Monitoring section are listed	🟢	All ten ER table rows present in ER order — alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, total bilirubin, thyroid-stimulating hormone, free thyroxine, total and free testosterone, morning serum cortisol, fasting glucose, complete blood count — with targets transcribed exactly.
14.3	[monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty.	🟢	Lines 775–779 capture every interval stated in the ER’s two monitoring paragraphs: baseline liver panel, liver enzymes at 8–12 weeks then annually, thyroid-stimulating hormone at 8 weeks, testosterone at 12 weeks, questionnaires at 4 and 8 weeks.

15. Qualitative Assessment

#	Description	Result	Comments
15.1	The section is derived from the ER Monitoring section	🟢	All eight items come from the ER’s “Qualitative markers worth tracking alongside the labs” list.
15.2	All subjective/qualitative biomarkers from the Monitoring section are listed	🟢	All eight ER bullets present in ER order, trimmed of trailing explanations but with no marker omitted.

Issues 02/09/2026 03:40

Pass rate 100.00%. No issues found.

Issues 02/09/2026 03:31

1. 2.5 — Imperative dosing instruction: action_3_sub at QRS lines 485–486 reads “Split 300 mg twice daily where daytime stress is the target”, a bare imperative that instructs rather than presents; the ER states it descriptively at ER 413 and 417 (“Split morning-and-evening dosing is used when daytime stress is the target”; “Split 300 mg twice daily is preferred where…”).
2. 4.3 — Abbreviated interaction label: The Key Interactions item at QRS line 612 shortens the ER’s bold label “Sedative and calming supplements” (ER 363) to “Sedative supplements”, the only one of the ten interaction labels not carried verbatim.

Fixes 02/09/2026 03:31

1. 2.5 — Imperative dosing instruction: Reworded action_3_sub from “Split 300 mg twice daily where daytime stress is the target” to “Split 300 mg twice daily is preferred where daytime stress is the target”, restoring the ER’s descriptive framing.
2. 4.3 — Abbreviated interaction label: Restored the ER’s bold label verbatim in the Key Interactions gate, changing “Sedative supplements” to “Sedative and calming supplements”.

Issues 02/09/2026 03:23

1. 4.5 — Sheet overruns one A4 page: At the template’s 800 px / 11 pt geometry the content renders to roughly two A4 pages — the Contraindications gate wraps to about 20 lines (lines 579–602), Key Interactions to about 19 (lines 609–633), and the ten-row Monitoring table (lines 681–823), its cadence paragraph and the eight Qualitative items (lines 841–887) carry near-ER-length prose that was never condensed to the per-section budget.
2. 9.2 — Interaction duplicates a contraindication: “Surgery and general anaesthesia” (line 633) restates the Contraindications entry “Within two weeks of elective surgery under general anaesthesia” (line 601) and, with its ER rationale stripped, carries no information the gate above does not already give.

Fixes 02/09/2026 03:23

1. 9.2 — Duplicated surgery interaction removed: Deleted the “Surgery and general anaesthesia” item from [caution_items]; the two-week pre-operative window is already carried by the Contraindications gate.
2. 4.5 — Contraindications gate condensed: Shortened all nine [stop_items] while keeping every population and its qualifier (e.g., “People with any chronic liver disease (cirrhosis of any severity, Child-Pugh Class A through C; chronic hepatitis B or C; fatty liver disease with scarring)” → “Chronic liver disease (cirrhosis Child-Pugh A–C, hepatitis B or C, fatty liver with scarring)”).
3. 4.5 — Interaction drug lists trimmed: Reduced the parenthetical example lists in [caution_items] to their leading representatives (e.g., sedatives to “benzodiazepines, zolpidem, gabapentin”; hepatotoxic botanicals to “green tea extract, Garcinia cambogia, red yeast rice”), preserving the ER bold labels verbatim.
4. 4.5 — Monitoring “Why” cells condensed: Rewrote all ten [marker_#_why] cells as short phrases (e.g., “Primary detector of the bile-flow and mixed liver injury reported with ashwagandha” → “Primary detector of the reported liver injury”) and shortened the complete-blood-count target to “Within reference limits, no downward trend”.
5. 4.5 — Cadence and qualitative items tightened: Compressed [monitoring_cadence] and shortened [qualitative_item_1], [qualitative_item_2], [qualitative_item_3], [qualitative_item_5], [qualitative_item_7] and [qualitative_item_8] without dropping any marker.